First State Approves Cannabis to Treat Opioid Addiction
On Monday, May 14, 2018, Pennsylvania became the first state to add opioid addiction to its list of approved conditions for medicinal cannabis. In a press release from Pennsylvania Governor Tom Wolf (1), it was stated that the Department of Health developed temporary regulations to implement the recommendations of the Medical Marijuana Advisory Board. These temporary regulations took effect on May 17, 2018.
The temporary regulations expand the number of serious medical conditions to include neurodegenerative diseases, terminal illness, dyskinetic and spastic movement disorders, and opioid-use disorder. “By adding opioid-use disorder as an approved medical condition under the program, we not only give physicians another tool for treatment of this devastating disease, but we allow for research to be conducted on medical marijuana’s effectiveness in treatment,” Secretary of Health Dr. Rachel Levine said in the press release. “Only approved conditions under the law can be studied through our research program.”
The research program also received approval for eight universities to become Certified Academic Clinical Research Centers in Pennsylvania’s medical marijuana program, signaling the first step toward clinical research to commence in the state. “The research component of Pennsylvania’s medical marijuana program sets it apart from the rest of the nation,” Governor Wolf said in the press release. “Today, medical research is so limited by the federal government that only a few doctors can even have access to medical marijuana. Pennsylvania’s premiere medical schools will be able to help shape the future of treatment for patients who are in desperate need not just here, but across the country.”
The eight approved universities include
- Drexel University College of Medicine, Philadelphia;
- Lewis Katz School of Medicine at Temple University, Philadelphia;
- Penn State College of Medicine, Hershey;
- Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia;
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia;
- University of Pittsburgh School of Medicine, Pittsburgh;
- Lake Erie College of Osteopathic Medicine (LECOM), Erie; and
- Philadelphia College of Osteopathic Medicine, Philadelphia.
References:
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
